Physician profile
Adam D Ray
NPI 1154371003
$5,017.44
in general payments reported to CMS, 2019-2025
20 companies · $846 in 2025
The $846 reported for 2025 was more than what 76% of Otolaryngology providers received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $400 · 2020: $146 · 2021: $421 · 2022: $1,532 · 2023: $754 · 2024: $919 · 2025: $846.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,519.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,518.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $1,917.72 | 2019-2025 | Scopis Ent, Fiagon Navigation Unit, Xpress Ent Dilation System |
| Astrazeneca Pharmaceuticals LP | $797.11 | 2021-2025 | Tezspire, Fasenra |
| Genzyme Corporation | $773.91 | 2020-2025 | |
| Inspire Medical Systems, INC. | $547.69 | 2023-2025 | Inspire |
| Optinose US, INC. | $178.20 | 2019-2021 | |
| Medtronic, INC. | $134.21 | 2022-2023 | Sinuva |
| Abbvie INC. | $115.34 | 2022 | |
| Aerin Medical INC. | $82.28 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $79.74 | 2024-2025 | Dupixent |
| Amgen INC. | $78.34 | 2024-2025 | Tezspire |
| Glaxosmithkline, LLC. | $52.94 | 2020-2022 | |
| Abbott Laboratories | $48.13 | 2023 | Mitraclip |
| Kaleo, INC. | $42.37 | 2021-2022 | |
| Acclarent, INC | $40.63 | 2020-2021 | |
| Intersect Ent, INC. | $28.76 | 2019-2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic USA, INC. | $26.07 | 2020 | |
| Merck Sharp & Dohme LLC | $19.10 | 2021 | |
| Arrinex, INC. | $18.79 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.34 | 2021 | |
| Neurent Medical Limited | $17.77 | 2025 | Neuromark System, Neuromark Radiofrequency Console |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adam Ray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.